Abstract
Among the clinical spectrum of neurological diseases, migraine is often associated with cerebro-vasculopathy. Impairment of neuroimmune mediators in the central nervous system has been recognized in the pathophysiology of migraine-related stroke. Although genetic correlation was found in patients with migraine-related stroke, the epidemiology of this disease indicates a need in biomarker searching discovery and validation. In this view, small molecule, called microRNAs (miRNAs), able to regulate immune and neuronal processes has been reported in patients with migraine and ischemic stroke and unambiguous miRNAs related to these diseases could be established as new molecular indicator of precocity for clinical and/or pharmacological intervention. Therefore, further exploration of this area is necessary, as greater understanding of these biomarkers could reveal the common mechanisms involved in the pathophysiology of migraine in patients with cerebral infarct.
Keywords: Cerebral infarct, cerebrovascular diseases, microRNA, migraine, neurological diseases, pathophysiology.
Graphical Abstract
MicroRNA
Title:microRNAs-based Predictor Factor in Patients with Migraine-ischemic Stroke
Volume: 6 Issue: 1
Author(s): Luca Gallelli, Antonio Siniscalchi*, Marco Carotenuto, Maria C. Caroleo, Erika Cione and Vincenzo Guidetti
Affiliation:
- Department of Neurology, Annunziata Hospital Via F. Migliori, 1; 87100 Cosenza,Italy
Keywords: Cerebral infarct, cerebrovascular diseases, microRNA, migraine, neurological diseases, pathophysiology.
Abstract: Among the clinical spectrum of neurological diseases, migraine is often associated with cerebro-vasculopathy. Impairment of neuroimmune mediators in the central nervous system has been recognized in the pathophysiology of migraine-related stroke. Although genetic correlation was found in patients with migraine-related stroke, the epidemiology of this disease indicates a need in biomarker searching discovery and validation. In this view, small molecule, called microRNAs (miRNAs), able to regulate immune and neuronal processes has been reported in patients with migraine and ischemic stroke and unambiguous miRNAs related to these diseases could be established as new molecular indicator of precocity for clinical and/or pharmacological intervention. Therefore, further exploration of this area is necessary, as greater understanding of these biomarkers could reveal the common mechanisms involved in the pathophysiology of migraine in patients with cerebral infarct.
Export Options
About this article
Cite this article as:
Gallelli Luca, Siniscalchi Antonio*, Carotenuto Marco, Caroleo C. Maria, Cione Erika and Guidetti Vincenzo, microRNAs-based Predictor Factor in Patients with Migraine-ischemic Stroke, MicroRNA 2017; 6 (1) . https://dx.doi.org/10.2174/2211536606666170104130101
DOI https://dx.doi.org/10.2174/2211536606666170104130101 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sequential Therapy For Helicobacter pylori in Elderly Patients: Effectiveness, Safety and Predictors of Success
Letters in Drug Design & Discovery PDE-5 Inhibitors: Clinical Points
Current Drug Targets Vascular Endothelium and Hypovolemic Shock
Current Vascular Pharmacology New Pharmacologic Horizons in the Treatment of Benign Prostatic Hyperplasia
Current Drug Therapy Human Platelets Express Authentic CB1 and CB2 Receptors
Current Neurovascular Research Editorial: [Hot Topic: Central Nervous System Drugs in the Treatment of Neurological Disorders]
Central Nervous System Agents in Medicinal Chemistry Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome
Current Molecular Medicine Susceptibility of Helicobacter pylori to Natural Products: Can Past Research Direct Future Drug Development?
Current Bioactive Compounds Non-Analgesic Effects of Opioids: The Cognitive Effects of Opioids in Chronic Pain of Malignant and Non-Malignant Origin. An Update.
Current Pharmaceutical Design Drug-Drug Interactions of Triazole Antifungal Agents in Multimorbid Patients and Implications for Patient Care
Current Drug Metabolism Biological Rationale for Regular Physical Exercise as an Effective Intervention for the Prevention and Treatment of Depressive Disorders
Current Pharmaceutical Design Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry New Insights into the Pathogenesis of Fibromyalgia Syndrome: Important Role of Peripheral and Central Pain Mechanisms
Current Rheumatology Reviews Management of Adult Active Tuberculosis Disease in Era of HIV Pandemic, Current Practices and Future Perspectives
Infectious Disorders - Drug Targets Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia
Current Drug Therapy Hepatotoxicity of Antiretroviral Drugs
Current Pharmaceutical Design Fast Disintegrating Film Approach for the Oral Delivery of Zolmitriptan: Formulation, <i>In Vitro</i> and <i>In Vivo</i> Evaluation
Drug Delivery Letters Drugs in Pediatric Ischemic Stroke
Current Drug Targets